Healing of Grade-II and III Oesophagitis through Motility Stimulation with Cisapride

Lepoutre, L; Spek, Pieter van der; Vanderlinden, I.; Bollen, J.; Laukens, P.

doi:10.1159/000200231

Cited by 36 publications

(8 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…can provide effective symptomatic relief and healing of esophagitis, with results comparable to cimetidine 400 mg q.i.d. or ranitidine 150 mg b.i.d., and superior to placebo (72)(73)(74). Combined therapy with cimetidine and either metoclopramide (10 mg q.i.d.)…”

Section: The Available Promotility Agents (Cisapride and Metoclopramimentioning

confidence: 99%

Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease

DeVault¹

1999

The American Journal of Gastroenterology

143

178

View full text Add to dashboard Cite

PREAMBLEGuidelines for the diagnosis and treatment of gastroesophageal reflux disease (GERD) were published by the American College of Gastroenterology in 1995 (1). These and other guidelines undergo periodic review. Significant advances have been made in the area of GERD over the past several years, leading us to review and revise our previous guidelines statements. These advances have included an increase in our comfort with the chronic use of proton pump inhibitors and an increased acceptance of laparoscopic antireflux surgery, among other factors. These and the original guidelines are intended to apply to all physicians who address GERD and are intended to indicate the preferable, but not only acceptable, approach. Physicians must always choose the course best suited to the individual patient and the variables that exist at the moment of the decision. These guidelines are intended to apply to adult patients with the symptoms, tissue damage, or both that result from the reflux of gastric contents into the esophagus. For the purpose of these guidelines GERD is defined as chronic symptoms or mucosal damage produced by the abnormal reflux of gastric contents into the esophagus.Both these and the original guidelines were developed under the auspices of the American College of Gastroenterology and its Practice Parameters Committee, and approved by the Board of Trustees. The world literature was reviewed extensively for the original guidelines and was once again reviewed using the National Library of Medicine database. All appropriate studies were reviewed and any additional studies found in the reference list of these papers were obtained and reviewed. Evidence was evaluated along a hierarchy, with randomized controlled trials given the greatest weight. Abstracts presented at national and international meetings were only used when unique data from ongoing trials were presented. When scientific data were lacking, recommendations were based on expert consensus. During preparation, the guidelines were reviewed

show abstract

Section: The Available Promotility Agents (Cisapride and Metoclopramimentioning

confidence: 99%

Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease

DeVault¹

1999

The American Journal of Gastroenterology

143

178

View full text Add to dashboard Cite

show abstract

“…Propagation velocity had to be neither more than 8-3 cm/s nor less than 1 cm/s; (8) nonpropagated contractions (no/24 h), defined as contraction waves that are not associated with a proximal contraction wave or have an apparent propagation velocity >8-3 cm/s. Several periods of interest were defined before analysisnamely, 24 …”

Section: Recording Devicementioning

confidence: 99%

“…acidity and motility were monitored under ambulatory conditions for 24 hours on the fourth day oftreatment, after a wash out period of 10 days during which patients received only antacids for relief of symptoms. Acid reflux was monitored by a pH electrode located 5 cm above the lower oesophageal sphincter.…”

mentioning

confidence: 99%

Effects of ranitidine and cisapride on acid reflux and oesophageal motility in patients with reflux oesophagitis: a 24 hour ambulatory combined pH and manometry study.

Inauen

Emde

Weber

et al. 1993

Gut

View full text Add to dashboard Cite

The effect of ranitidine and cisapride on acid reflux and oesophageal motility was investigated in 18 patients with endoscopically verified erosive reflux oesophagitis. Each patient was treated with placebo, ranitidine (150 mg twice daily), and ranitidine (150 mg twice daily) plus cisapride (20 mg twice daily) in a double blind, double dummy, within subject, three way cross over design. Oesophageal acidity and motility were monitored under ambulatory conditions for 24 hours on the fourth day oftreatment, after a wash out period of 10 days during which patients received only antacids for relief of symptoms. Acid reflux was monitored by a pH electrode located 5 cm above the lower oesophageal sphincter. Intraoesophageal pressure was simultaneously recorded from four transducers placed 20, 15, 10, and 5 cm above the lower oesophageal sphincter. Upright reflux was three times higher than supine reflux (median (range) 13-3 (3 7-35 0)% v 3-7 (0-37-6)% of the time with pH<4*0, p<001, n=18). Compared with placebo, ranitidine decreased total reflux (from 10*0 (3.2-32.6)% to 6-4 (1.2-22-9)%, p<001), upright reflux (p<005), supine reflux (p<0001), and postprandial reflux (p<0-01), but did not affect oesophageal motility. The combination of ranitidine with cisapride further diminished the acid reflux found with ranitidine -that is, cisapride led to an additional reduction of total reflux (from 6*4 (1-2-22.9)% to 3-7 (1.0-12.7)%, p<001), supine reflux (p<0.05), and postprandial reflux (p

show abstract

“…Cisapride was shown to be superior to placebo (4,5) and comparable with cimetidine and ranitidine in producing endoscopically shown mucosal healing ( 6 8 ) . In one placebo-controlled trial in the USA, healing rates during treatment with cisapride were lower than those reported in Europe (9).…”

mentioning

confidence: 99%

Effect of Cisapride on Relapse of Reflux Oesophagitis, Healed with an Antisecretory Drug

Tytgat

Hansen

Carling

et al. 1992

Scandinavian Journal of Gastroenterology

View full text Add to dashboard Cite

Maintenance treatment with cisapride was evaluated in 298 patients in whom reflux oesophagitis had been healed with antisecretory drugs. Initially, 34% of the patients had grade-I oesophagitis, 33% had grade II, and 33% had grade III. The patients were treated with 20 mg cisapride twice daily or placebo for 6 months or until endoscopic relapse was shown if this occurred earlier. Survival analysis showed that cisapride significantly prolonged the time to endoscopic relapse in grade-I patients (P = 0.02). The intergroup difference in symptomatic relapse in all patients was also significant (P = 0.010). The effect of cisapride was less clearcut in grade II or III, and/or in patients healed with omeprazole. Factors associated with early relapse were placebo therapy, prior omeprazole therapy, duration of pre-trial symptomatic period, and initial endoscopic severity grade. Adverse experiences were limited; diarrhoea was reported by 9% of the cisapride patients.

show abstract

Healing of Grade-II and III Oesophagitis through Motility Stimulation with Cisapride

Cited by 36 publications

References 11 publications

Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease

Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease

Effects of ranitidine and cisapride on acid reflux and oesophageal motility in patients with reflux oesophagitis: a 24 hour ambulatory combined pH and manometry study.

Effect of Cisapride on Relapse of Reflux Oesophagitis, Healed with an Antisecretory Drug

Contact Info

Product

Resources

About